Tate & Lyle stock advances on full-year 2025 profit and cash flow

Tate & Lyle plc (ISIN GB0008707753) is framed by fiscal 2025 results that showed GBP 2.08 billion in revenue, adjusted EBITDA of GBP 392 million, and adjusted free cash flow of GBP 242 million. The numbers give the Tate & Lyle stock story a clear anchor even on a thin day.

GBP 2.08 billion revenue

For fiscal 2025, Tate & Lyle reported revenue of GBP 2.08 billion, while adjusted EBITDA reached GBP 392 million. Adjusted free cash flow came in at GBP 242 million for the year, which matters because cash generation often carries more weight than simple headline growth in ingredient businesses.

The comparison is straightforward: revenue, EBITDA, and free cash flow were all reported as full-year figures for fiscal 2025, and the cash figure of GBP 242 million shows the company converting earnings into liquidity rather than only accounting profit.

Adjusted EBITDA at GBP 392 million

Adjusted EBITDA of GBP 392 million for fiscal 2025 is the most useful profit line for reading operating momentum. It strips out some non-recurring items and lets investors compare the underlying business more cleanly than reported earnings alone.

Adjusted free cash flow of GBP 242 million adds a second layer to that picture. A company with 2.08 billion pounds of sales and 392 million pounds of adjusted EBITDA is being judged not just on margin, but on whether that margin reaches cash.

Cash flow matters more

In ingredient and sweetener markets, cash conversion can matter as much as revenue size. Tate & Lyle’s GBP 242 million adjusted free cash flow in fiscal 2025 is therefore a central number, because it helps explain how the company funds debt, dividends, and investment.

That makes the stock narrative less about a single day’s move and more about whether fiscal 2025 can sustain operating discipline into the next reporting cycle.

Product focus stays narrow

For Tate & Lyle, the relevant product lens is still its ingredients portfolio rather than a single consumer brand. In the absence of a fresh product launch in the available material, the fiscal 2025 numbers remain the strongest way to read the stock.

Stock line remains omitted

Tate & Lyle shares are listed in London, and the company remains tied to the ingredients and food solutions segment. A dated price line was not used here, so the body relies on the fiscal 2025 revenue, EBITDA, and free cash flow metrics instead.